Echo Therapeutics (NSDQ:ECTE) said today it won Institutional Review Board approval to expand testing of its non-invasive continuous glucose monitor, which can now include both pediatric and adult subjects.
The Iselin, N.J.-based company is developing a non-invasive, wireless CGM for use in the outpatient diabetes market and the fitness, weight loss and personal lifestyle wearable-health space.
“We are very excited about the approval of our new clinical protocol. This important achievement enables the company to dramatically expand the clinical testing of our CGM system on a diverse population, including adolescents and children. Initial studies, testing components of our NextGen system, are expected to begin in the coming weeks,” CEO Scott Hollander said in a press release.
Last July, Echo Therapeutics said it is moving its research lab from Franklin, Mass. to Littleton, Mass. and terminating its previous lease in the process.
The developer of wireless glucose monitors and wearable health and fitness devices said it paid $150,000 to break the lease on its previous 37,050 square foot research facility in Franklin.
Echo Therapeutics relocated on July 3 to a smaller 10,132 square foot research facility in Littleton, Mass., according to an SEC filing from the company.